235 related articles for article (PubMed ID: 20530656)
1. Photodynamic therapy combined with ranibizumab for polypoidal choroidal vasculopathy: results of a 1-year preliminary study.
Ruamviboonsuk P; Tadarati M; Vanichvaranont S; Hanutsaha P; Pokawattana N
Br J Ophthalmol; 2010 Aug; 94(8):1045-51. PubMed ID: 20530656
[TBL] [Abstract][Full Text] [Related]
2. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month MONT BLANC study results.
Larsen M; Schmidt-Erfurth U; Lanzetta P; Wolf S; Simader C; Tokaji E; Pilz S; Weisberger A;
Ophthalmology; 2012 May; 119(5):992-1000. PubMed ID: 22424834
[TBL] [Abstract][Full Text] [Related]
3. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy.
Koh A; Lee WK; Chen LJ; Chen SJ; Hashad Y; Kim H; Lai TY; Pilz S; Ruamviboonsuk P; Tokaji E; Weisberger A; Lim TH
Retina; 2012 Sep; 32(8):1453-64. PubMed ID: 22426346
[TBL] [Abstract][Full Text] [Related]
4. Verteporfin plus ranibizumab for choroidal neovascularization in age-related macular degeneration: twelve-month results of the DENALI study.
Kaiser PK; Boyer DS; Cruess AF; Slakter JS; Pilz S; Weisberger A;
Ophthalmology; 2012 May; 119(5):1001-10. PubMed ID: 22444829
[TBL] [Abstract][Full Text] [Related]
5. 1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy.
Wong IY; Shi X; Gangwani R; Zhao P; Iu LP; Li Q; Ng A; Li X
BMC Ophthalmol; 2015 Jun; 15():66. PubMed ID: 26122636
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy.
Lai TY; Chan WM; Liu DT; Luk FO; Lam DS
Br J Ophthalmol; 2008 May; 92(5):661-6. PubMed ID: 18356265
[TBL] [Abstract][Full Text] [Related]
7. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series.
Chan WM; Lam DS; Lai TY; Liu DT; Li KK; Yao Y; Wong TH
Ophthalmology; 2004 Aug; 111(8):1576-84. PubMed ID: 15288991
[TBL] [Abstract][Full Text] [Related]
8. Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy.
Maruko I; Iida T; Sugano Y; Saito M; Sekiryu T
Am J Ophthalmol; 2011 Apr; 151(4):594-603.e1. PubMed ID: 21295766
[TBL] [Abstract][Full Text] [Related]
9. Comparisons of outcomes with different intervals between adjunctive ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy.
Sato T; Kishi S; Matsumoto H; Mukai R
Am J Ophthalmol; 2013 Jul; 156(1):95-105.e1. PubMed ID: 23628354
[TBL] [Abstract][Full Text] [Related]
10. Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study.
Brown DM; Michels M; Kaiser PK; Heier JS; Sy JP; Ianchulev T;
Ophthalmology; 2009 Jan; 116(1):57-65.e5. PubMed ID: 19118696
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal ranibizumab combined with verteporfin photodynamic therapy for treating polypoidal choroidal vasculopathy.
Lee YH; Lee EK; Shin KS; Lee KM; Kim JY
Retina; 2011; 31(7):1287-93. PubMed ID: 21386762
[TBL] [Abstract][Full Text] [Related]
12. INITIAL VERSUS DELAYED PHOTODYNAMIC THERAPY IN COMBINATION WITH RANIBIZUMAB FOR TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY: The Fujisan Study.
Gomi F; Oshima Y; Mori R; Kano M; Saito M; Yamashita A; Iwata E; Maruko R;
Retina; 2015 Aug; 35(8):1569-76. PubMed ID: 25830698
[TBL] [Abstract][Full Text] [Related]
13. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study.
Heier JS; Boyer DS; Ciulla TA; Ferrone PJ; Jumper JM; Gentile RC; Kotlovker D; Chung CY; Kim RY;
Arch Ophthalmol; 2006 Nov; 124(11):1532-42. PubMed ID: 17101999
[TBL] [Abstract][Full Text] [Related]
14. Photodynamic therapy, ranibizumab, and ranibizumab with photodynamic therapy for the treatment of polypoidal choroidal vasculopathy.
Rouvas AA; Papakostas TD; Ntouraki A; Douvali M; Vergados I; Ladas ID
Retina; 2011 Mar; 31(3):464-74. PubMed ID: 20948458
[TBL] [Abstract][Full Text] [Related]
15. Combination treatment of photodynamic therapy with verteporfin and intravitreal ranibizumab in patients with retinal angiomatous proliferation.
Seidel G; Werner C; Weger M; Steinbrugger I; Haas A
Acta Ophthalmol; 2013 Sep; 91(6):e482-5. PubMed ID: 23786546
[TBL] [Abstract][Full Text] [Related]
16. Three-year visual outcomes of intravitreal ranibizumab with or without photodynamic therapy for polypoidal choroidal vasculopathy.
Sakai T; Okano K; Kohno H; Tsuneoka H
Acta Ophthalmol; 2016 Dec; 94(8):e765-e771. PubMed ID: 27237048
[TBL] [Abstract][Full Text] [Related]
17. Reduced-fluence photodynamic therapy in polypoidal choroidal vasculopathy nonresponsive to ranibizumab.
Byon IS; Kwon HJ; Kim SI; Shin MK; Park SW; Lee JE
Ophthalmic Surg Lasers Imaging Retina; 2014; 45(6):534-41. PubMed ID: 25423633
[TBL] [Abstract][Full Text] [Related]
18. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab.
Tomita K; Tsujikawa A; Yamashiro K; Ooto S; Tamura H; Otani A; Nakayama Y; Yoshimura N
Am J Ophthalmol; 2012 Jan; 153(1):68-80.e1. PubMed ID: 21907965
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month LAPTOP study results.
Oishi A; Kojima H; Mandai M; Honda S; Matsuoka T; Oh H; Kita M; Nagai T; Fujihara M; Bessho N; Uenishi M; Kurimoto Y; Negi A
Am J Ophthalmol; 2013 Oct; 156(4):644-51. PubMed ID: 23876867
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.
Koh A; Lai TYY; Takahashi K; Wong TY; Chen LJ; Ruamviboonsuk P; Tan CS; Feller C; Margaron P; Lim TH; Lee WK;
JAMA Ophthalmol; 2017 Nov; 135(11):1206-1213. PubMed ID: 28983556
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
